The present invention provides methods and systems to accurately detect and measure levels of endogenous antibodies, for examples endogenous IgA, to particular antigens in a biological sample from a companion animal, which is useful to diagnose inflammatory conditions, including bowel disease (IBD), gastrointestinal infections, and food sensitivities in companion animals, e.g., dogs or cats, and to distinguish among such gastrointestinal disorders. Such methods and systems identify whether a sample from the patient is associated with an inflammatory condition, infection, and/or food sensitivity condition, by using non-invasive means, thus conveniently providing information useful for guiding treatment decisions.

A sensor for detecting an analyte of interest in a fluid sample includes (i) a structure having a plurality of surficial walls that define a plurality of air gaps in the structure and (ii) a binding material. The structure is configured such that both a fluid sample lacking the analyte of interest and a fluid sample containing the analyte of interest are able to penetrate the plurality of air gaps. The binding material, which is present on the plurality of surficial walls, is able to bind the analyte of interest. The sensor is configured such that, when the analyte of interest binds to the binding material, a change in surface energy results within the plurality of surficial walls.

The present invention is the protein of lactoferrin, or an encoding nucleic acid of same, for use in the diagnosis or prognosis of Alzheimer's disease (AD). The invention is a method of diagnosis or prognosis of AD in a subject, comprising assessing the level of lactoferrin in the saliva or in a saliva sample of said subject and determining whether said level is above or below a value of 7.43 μg/ml, wherein a value below 7.43 μg/ml is indicative of AD or of the prognosis of AD. Another aspect is the protein of lactoferrin, or an encoding nucleic acid of same, for use in the diagnosis of Parkinson's disease (PD) in a saliva sample of a subject.

The present disclosure provides use of a reagent for detecting an expression level of transferrin in the preparation of a diagnostic reagent or kit for a disease caused by imbalance of intestinal immune tolerance, and belongs to the technical field of medical molecular biology. In the present disclosure, the severity of intestinal inflammatory diseases is diagnosed according to the transferrin level, achieving the objective of the early diagnosis of the disease caused by imbalance of intestinal immune tolerance. In the present disclosure, the transferrin is used as a marker for imbalance of intestinal immune tolerance, featuring high specificity and sensitivity, and simple detection procedure.

Engineered protein electron carriers, microorganisms expressing the same, and methods detecting regulated electron flow are described.

The invention encompasses methods and test strips for detecting the presence of cerebrospinal fluid (CSF) in a biological sample comprising removing sialo-transferrin and selectively detecting or measuring asialo-transferrin in the biological sample.

A method screens for aptamers by using a microarray microfluidic chip. The screening chip integrates microarray and microfluidic technology to integrate the positive and negative screening process on a microfluidic chip, and obtains aptamers with high affinity after 7 rounds of screening. It also discloses specific steps for screening of lactoferrin aptamers, including detailed processes such as chip preparation, positive and negative screening processes, and PCR amplification. The aptamers screened by the method have good specificity and affinity to the target protein. The aptamers are easier to be obtained than the antibody, and can be synthesized rapidly in large quantities in vitro. The preparation method is simpler and faster, so aptamers are expected to be a useful complement to antibody technology in many areas.

The invention encompasses methods and test strips for detecting the presence of cerebrospinal fluid (CSF) in a biological sample comprising removing sialo-transferrin and selectively detecting or measuring asialo-transferrin in the biological sample.

The present invention provides methods and systems to accurately detect and measure levels of endogenous antibodies, for examples endogenous IgA, to particular antigens in a biological sample from a companion animal, which is useful to diagnose inflammatory conditions, including bowel disease (IBD), gastrointestinal infections, and food sensitivities in companion animals, e.g., dogs or cats, and to distinguish among such gastrointestinal disorders. Such methods and systems identify whether a sample from the patient is associated with an inflammatory condition, infection, and/or food sensitivity condition, by using non-invasive means, thus conveniently providing information useful for guiding treatment decisions.

The present invention provides methods and systems to accurately detect and measure levels of endogenous antibodies, for examples endogenous IgA, to particular antigens in a biological sample from a companion animal, which is useful to diagnose inflammatory conditions, including bowel disease (IBD), gastrointestinal infections, and food sensitivities in companion animals, e.g., dogs or cats, and to distinguish among such gastrointestinal disorders. Such methods and systems identify whether a sample from the patient is associated with an inflammatory condition, infection, and/or food sensitivity condition, by using non-invasive means, thus conveniently providing information useful for guiding treatment decisions.